Nvidia (NVDA) is moving further into the biomedical space with a new software tool that equips AI agents to perform scientific work.
Called the BioNeMo Agent Toolkit, the software is agent agnostic, meaning it can work across various AI agents, such as OpenAI’s (OPAI.PVT) Codex.
According to Nvidia vice president of healthcare Kimberly Powell, the toolkit equips AI agents with the knowledge necessary to perform specific medical research more efficiently.
“In the world of agents, the longer the agent is waiting … the more tokens you will be burning. And so we need to have accelerated tools for the agents to work with,” Powell explained.
Nvidia CEO Jensen Huang. (AP foto/Chiang Ying-ying) · AP Photo/Chiang Ying-ying
Think of the BioNeMo toolkit as a crash course in specific scientific and medical understanding for an AI agent.
Asking a general agent like OpenAI’s Codex or Anthropic’s (ANTH.PVT) Claude for highly specialized medical or scientific questions, Powell explained, would likely take some time, if the agents could answer at all.
“If you gave a general agent and you asked them to go build a protein binder, it probably wouldn’t be able to do anything, and it would spend a whole bunch of tokens … trying to decide which model to use and reading all of this literature,” she said.
“We’re now giving all of that understanding and know-how right into the agent systems,” Powell added.
Nvidia said the toolkit will enable agents to help researchers find “small-molecule drug candidates,” assist with genomic analysis, and aid in medical imaging analysis.
Nvidia offers a wide variety of open-source software under its line of Nemotron open-weight AI models, which provide enhanced capabilities for customers while ensuring they’ll continue to rely on the company for chips in the future.
Sign up for Yahoo Finance’s Week in Tech newsletter. · Yahoo Finance
Email Daniel Howley at dhowley@yahoofinance.com. Follow him on Twitter at @DanielHowley.
Click here for the latest technology news that will impact the stock market
Read the latest financial and business news from Yahoo Finance